Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the university of Iowa/mayo clinic specialized program of research excellence molecular epidemiology resource

Brian K. Link, Matthew J. Maurer, Grzegorz S. Nowakowski, Stephen M. Ansell, William R. MacOn, Sergei I. Syrbu, Susan L. Slager, Carrie A. Thompson, David J. Inwards, Patrick B. Johnston, Joseph P. Colgan, Thomas E. Witzig, Thomas M. Habermann, James R. Cerhan

Research output: Contribution to journalArticle

161 Scopus citations

Abstract

Purpose: This study sought to characterize transformation incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational series begun after diffusion of rituximab use. Patients and Methods: Patients with newly diagnosed FL were prospectively enrolled onto the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource from 2002 to 2009. Patients were actively followed for re-treatment, clinical or pathologic transformation, and death. Risk of transformation was analyzed via time to transformation by using death as a competing risk. Results: In all, there were 631 patients with newly diagnosed grade 1 to 3a FL who had a median age at enrollment of 60 years. At a median follow-up of 60 months (range, 11 to 110 months), 79 patients had died, and 60 patients developed transformed lymphoma, of which 51 were biopsy proven. The overall transformation rate at 5 years was 10.7%, with an estimated rate of 2% per year. Increased lactate dehydrogenase was associated with increased risk of transformation. Transformation rate at 5 years was highest in patients who were initially observed and lowest in patients who initially received rituximab monotherapy (14.4% v 3.2%; P = .021). Median overall survival following transformation was 50 months and was superior in patients with transformation greater than 18 months after FL diagnosis compared with patients with earlier transformation (5-year overall survival, 66% v 22%; P lt; .001). Conclusion: Follicular transformation rates in the immunochemotherapy era are similar to risk of death without transformation and may be lower than reported in older series. Post-transformation prognosis is substantially better than described in older series. Initial management strategies may influence the risk of transformation.

Original languageEnglish (US)
Pages (from-to)3272-3278
Number of pages7
JournalJournal of Clinical Oncology
Volume31
Issue number26
DOIs
StatePublished - Sep 10 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the university of Iowa/mayo clinic specialized program of research excellence molecular epidemiology resource'. Together they form a unique fingerprint.

  • Cite this